Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk's market value plummeted by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO. The company slashed its 2025 sales growth outlook due to ...

GLP-1 drugs are widely seen as a transformative treatment, and their vast market potential is now the industry consensus, WuXi AppTec said. The company’s outsourcing model allows it to contribute to ...